# FC Capital

> FC Capital is a VC fund in Shanghai backing Medical, Health Care and Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 10
- Last investment: Apr 2025
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/丰川资本-fc-capital
- Website: http://www.fccapital.cn

FC Capital is a VC fund in Shanghai focused on Medical and Health Care. Fengchuan Capital is a private equity investment firm focused on the complete medical and pharmaceutical industry chain, including cutting-edge biomedicine, the transformation of original inventive enterprises, and pharmaceutical cross-border integration.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 6 | 60% |
| Health Care | 4 | 40% |
| Biotechnology | 4 | 40% |
| Biopharma | 3 | 30% |
| Therapeutics | 3 | 30% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 50% |
| Series B | 2 | 20% |
| Series C | 2 | 20% |
| Seed | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 7 | 70% |
| Switzerland | 1 | 10% |
| United States | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| iRegene | iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases. | $13.7M | Series B | Apr 11, 2025 |  |
| Degron Therapeutics | Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. |  | Series A | Jan 22, 2025 |  |
| Enokiko | Enokiko is a provider of synthetic biology platforms oriented to the study, creation, and manufacturing of environmentally friendly biological products. | $13.7M | Seed | Nov 03, 2023 |  |
| VJTbio | Weijiexin focuses on the high-end animal protein pharmaceutical market. It is a biopharmaceutical business that combines R&D, medicine production, and sales for cutting-edge treatments for animal health. |  | Series C | May 22, 2023 |  |
| Lupeng Pharmaceutical | Lupeng Pharmaceutical is a clinical-stage company that focuses on the drug discovery and development of novel therapies for cancer treatment. | $35M | Series A | Nov 14, 2022 |  |
| Rona Therapeutics | Rona Therapeutics is a RNA therapeutics platform enabling discovery and development of modular and programmable RNA medicines. | $33M | Series A | Apr 07, 2022 |  |
| Harvest Integrated Research Organization | Harvest Integrated Research Organization is a China-based, globally-oriented clinical research organization. | $1.6M | Series A | Mar 17, 2022 |  |
| Cellestia | Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistantcancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland. | $23.3M | Series B | Dec 17, 2019 |  |
| Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $16.6M | Series C | Sep 23, 2019 |  |
| Cellestia | Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistantcancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland. | $23.3M | Series A | Dec 19, 2018 |  |

10 of 10 investments shown.

## Co-investors
- FC Capital — VC Fund, 3 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [Partners Investment](https://shizune.co/investors/profile/partners-investment) — VC Fund, 2 deals together
- [PPF Group](https://shizune.co/investors/profile/ppfgroup) — VC Fund, 2 deals together
- AIM-HI Accelerator Fund — VC Fund, 1 deal together
- [Beijing Capital Science and Technology Development Group](https://shizune.co/investors/profile/beijing-capital-science-and-technology-development-group) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does FC Capital invest in?

FC Capital invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did FC Capital last invest?

The most recent investment recorded for FC Capital closed in Apr 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co